title: [Comparative study on the efficacy of Hyper CVAD/MA regimen and CHOP or CHOP like regimen in the treatment of primary peripheral T cell lymphoma].
abstract: OBJECTIVE
  To evaluate the curative efficacy and safety of two regimens, Hyper CVAD/MA and CHOP/CHOP, in the treatment of primary peripheral T cell lymphoma (PTCL).
  
  
  METHODS
  The clinical data of 80 primary PTCL patients were retrospectively analyzed, and the efficacy and safety of the two regimens, Hyper CVAD/MA and CHOP/CHOP, were evaluated.
  
  
  RESULTS
  Of 80 patients with primary PTCL, 23 were treated with Hyper CVAD/MA regimen (HM group, experimental group) and 57 with CHOP or CHOP-like regimen (CC group, control group). The differences between overall response rate (ORR) among HM group and CC group (78.3% vs 54.4%, P = 0.047), ORR in patients with IPI score of 0-2 (86.7% vs 55.2%, P = 0.037), courses of chemotherapy to achieve remission (4 vs 6, P = 0.004), median progression-free survival (PFS) time (24 months vs 12 months, P = 0.039) and 1- year PFS rate (82.6% against 45.6%, P = 0.006) were statistically significant. The relapse rates were similar between 2 groups (50.0% vs 54.8%, P = 0.744). The 2-year and 3-year progression-free survivals and 3 year overall survival were not significantly different (P > 0.05). Patients in Hyper CVAD/MA group are more susceptible to neutropenia (<1.5 × 10⁹/L) (73.9% vs 38.6%, P=0.004).
  
  
  CONCLUSIONS
  The curative effect of Hyper CVAD/MA regimen as induction therapy in treatment of PTCL patients except ALK positive PTCL patients was better than that of CHOP/CHOP-like regimen.
authors.affiliation: Department of Hematology, Changhai Hospital, Shanghai 200433, China.
authors.forename: Jin
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Hematology, Changhai Hospital, Shanghai 200433, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Gao
authors.affiliation: Department of Hematology, Changhai Hospital, Shanghai 200433, China.
authors.forename: Huiying
authors.initials: H
authors.lastname: Qiu
authors.affiliation: Department of Hematology, Changhai Hospital, Shanghai 200433, China.
authors.forename: Weiping
authors.initials: W
authors.lastname: Zhang
authors.affiliation: Department of Hematology, Changhai Hospital, Shanghai 200433, China.
authors.forename: Jianmin
authors.initials: J
authors.lastname: Yang
authors.affiliation: Department of Hematology, Changhai Hospital, Shanghai 200433, China.
authors.forename: Xianmin
authors.initials: X
authors.lastname: Song
authors.affiliation: Department of Hematology, Changhai Hospital, Shanghai 200433, China.
authors.forename: Shuqing
authors.initials: S
authors.lastname: Lyu
authors.affiliation: Department of Hematology, Changhai Hospital, Shanghai 200433, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Chen
authors.affiliation: Department of Hematology, Changhai Hospital, Shanghai 200433, China.
authors.forename: Jianmin
authors.initials: J
authors.lastname: Wang
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018572:Disease-Free Survival; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local; D012189:Retrospective Studies